Cultivation of live cold-adapted reassortant influenza vaccine


Cite item

Full Text

Abstract

Optimal conditions for the cultivation of the MDCK cell lines in the laboratory spinner or by using the Eagle-MEM with or without fetal serum were worked out. The cold-adapted reassortant vaccine strains of virus influenza A/ H1N1, A/H3N2 and В are well replicated in the MDCK cells both in a monolayer and in the spinner by using the serum-free medium. A maximum virus titer depends on a multiplicity of infection used in a fetal medium and on the addition of trypsin. Under the optimal conditions, the titer of the studied cold-adapted reassortants, while using a serum-free medium, reaches as much as 1090 - 10" EIDM/ml.

References

  1. Гендон Ю. 3. Культуральные гриппозные вакцины // Вопр. вирусол. - 2002. - № 6. - С. 4-11.
  2. Киселева И. В., Александрова Г. И., Науменко 3. С. и др. Культура клеток MDCK - возможный субстрат для производства живой гриппозной вакцины // Актуальные проблемы медицинской вирусологии. - М., 1999. - Т. 1. - С. 104.
  3. Boycott К., Klenk H., Ohuchi М. Cell tropism of influenza virus entry // Virology. - 1994. - Vol. 203. - P. 313-319.
  4. Brands R., Visser J., Medema J. et al. lnfluvac: A safe Madin Darby canine kidney (MDCK) cell culture-based influenza vaccine // Dev. Biol. Stand. - 1999. - Vol. 98. - P. 93-100.
  5. Butel J. Simian virus 40, poliovirus vaccines and human cancer: research progress versus media and public interest // Bull. Wld Hlth Org. - 2000. - Vol. 78. - P. 195-198.
  6. Byassard D., Lamb R. Expression of influenza В virus containing multibasic residual cleavage site // Virology. - 1997. - Vol. 236. - P. 234-248.
  7. Ghendon Y. Influenza vaccines: a main problem in control of pandemics // Eur. J. Epidemiol. - 1994. - Vol. 10. - P. 485486.
  8. Ghendon Y. Cold-adapted live influenza vaccines developed in Russia // Textbook of Influenza / Eds K. Nicholson et al. - 1998. - P. 391-399.
  9. Halperin S., Nestruck A., Eastwood B. Safety and immunogenicity of a new influenza vaccine grown in mammalian cell culture // Vaccine. - 1998. - Vol. 16. - P. 1331-1335.
  10. Halperin S., Smith В., Mabrouk T. et al. Safety and immunogenicity of trivalent inactivated mammalian cell culture-derived influenza vaccine in healthy adults, seniors and children // Vaccine. - 2002. - Vol. 20. - P. 1240-1247.
  11. Kawaoka Y., Webster R. Sequence requirements for cleavage activation of influenza vims hemagglutinin expressed in mammalian cells // Proc. Natl. Acad. Sci. USA. - 1988. - Vol. 85. P. 324-328.
  12. Kistner O., Barrett P., Mundt W. et al. Development of a mammalian cell (Vera) derived candidate influenza virus vaccine // Vaccine. - 1998. - Vol. 16. - P. 960-968.
  13. Kistner O., Barrett P., Mundt W. et al. Development at a novel influenza vaccine derived from a continuous cell line // Altex. - 2001. - Vol. 18. - P. 50-54.
  14. Klenk H., Rott R., Orlich M. et al. Activation of influenza A virus by tripsin treatment // Virology. - 1975. - Vol. 68. - P. 429- 439.
  15. Lazarowitz I., Choppin P. Enhancement of the infectivity of influenza A and В viruses by proteolytic cleavage of the hemagglutinin polypeptide // Ibid. - P. 440-454.
  16. Merten O., Managuerra J., Hannoun C. et al. Production of influenza virus in serum-free mammalian cell cultures // Dev. Biol. Stand. - 1999. - Vol. 98. - P. 23-37.
  17. Palache A., Scheepers H., de Regt V. et al. Safety, reactogenicity and immunogenicity of Mardin Darby canine kidney cell-derived inactivated influenza subunit vaccine. A meta-analysis of clinical studies // Ibid. - P. 115-125.
  18. Petricciani J. Regulatory philosophy and acceptability of cells for production of biologicals // Ibid. - 1991. - Vol. 75. - P. 915.
  19. Poland G. Lessons from the influenza vaccine recall of 1996- 1997 // J. A. M. A. - 1997. - Vol. 278. - P. 1022-1023.
  20. Robertson J., Bootman G., Nicholson C. et al. The hemagglutinin of influenza В virus present in clinical material is a single species identical to that of mammalian cell-grown virus // Virology. - 1990. - Vol. 179. - P. 35-40.
  21. Robertson J. Clinical influenza virus and the embryonated hen's egg // Rev. Med. Virol. - 1993. - Vol. 3. - P. 97-106.
  22. Schild G., Oxford J., de Jong J. et al. Evidence for host-cell selection of influenza virus antigenic variants // Nature. - 1983. - Vol. 303. - P. 706-709.
  23. Steinhauer D., Wharon S. Structure and function of the hemagglutinin // Textbook of Influenza / Eds K. Nicholson et al. - 1998. - P. 54-64.
  24. Steinhauer D. Role of hemagglutinin cleavage for the pathogenecity of influenza virus // Virology. - 1999. - Vol. 258. - P. 1-20.
  25. Waters Т., Beeb J., Miller W. Yellow fever vaccination, avian leucosis and cancer risk in man // Science. - 1972. - Vol. 177. - P. 76-77.
  26. WHO. Requirements for the use of animal cells as in vitro substrate for the production of biologicals // Requirements for Biological Substances N 50, WHO Techn. Rep. Ser. - 1998. N878.-Annex 1. - P. 20-56.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2003 Gendon Y.Z., Markushin S.G., Akopova I.I., Koptyayeva I.B., Isachenko A.A., Mazurkova N.A., Nechyeva E.A.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС77-77676 от 29.01.2020.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies